OBJECTIVE: To assess the efficacy and pathological change of fertility-sparing treatment with @entity1871 for @entity1204 ( @entity1204 ) of stage I a and @entity1373 ( @entity1373 ) and to observe the prognosis of the treatment. METHODS: Nine @entity1204 @entity1 of stage I a and 21 @entity1373 @entity1 aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All @entity1 were given a daily oral high-dose of @entity1871 with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for @entity1 with complete response (CR). RESULTS: During the first period of fertility-sparing management, according to histologic change, 5 @entity1204 @entity1 and 18 @entity1373 @entity1 showed CR with no evidence of @entity1204 or @entity1373 , 2 @entity1204 @entity1 and 2 @entity1373 @entity1 showed partial response with a regression to @entity1869 without atypia, 2 @entity1204 @entity1 and 1 @entity1373 @entity1 showed stable disease or @entity74 . Accordingly, a total of 26 @entity1 showed CR (26 of 30 @entity1 ). The median time to CR was 6 months (range, 3 to 21 months) of @entity1871 treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all @entity1 were alive. During follow-up, among the 26 @entity1 with CR, 3 of 6 @entity1204 @entity1 achieved @entity66 after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 @entity1373 @entity1 achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 @entity1373 with recurrent disease achieved CR to @entity1871 re-treatment. Eight of 26 @entity1 achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped @entity1420 treatment after CR and 7 @entity1 had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). @entity1204 @entity1 succeeded in 4 pregnancies, @entity1373 @entity1 succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all. CONCLUSIONS: @entity1204 of stage I a and @entity1373 had slow progression of symptoms. @entity1871 treatment in @entity1204 of stage I a and @entity1373 @entity1 was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. @entity1871 re-treatment in most @entity1 with recurrent @entity1204 is effective and safe.

[Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with @entity1871 for @entity1204 of stage I a and XXXX ].

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma', 'endometrial adenocarcinoma', 'endometrial cancer', 'EC'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['CR recurred disease'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['complex atypical hyperplasia', 'CAH', 'hyperplasia'] @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['Progestin', 'progestin'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease'] @entity1869 :: ('MESH:D004714', 'Disease') :: ['complex or simple hyperplasia']
@entity1373 :: (MESH:D006965,Disease) :: ['complex atypical hyperplasia']
